logo-loader

Genprex rakes in $8M in at-the-market stock offering

Published: 10:10 23 Jan 2020 EST

Moneybags changing hands
Genprex is developing a new approach to treating cancer, including its initial product candidate Oncoprex, which is an immunogene therapy for non-small cell lung cancer

Genprex Inc (NASDAQ:GNPX) announced an $8 million offering of stock through securities purchase agreements made with influential investors.  

The gene therapy company sold 7.6 million shares at a price of $1.05 per share, in accordance with Nasdaq rules governing registered direct offerings. 

READ: Genprex wins FDA Fast Track status for its Oncoprex therapy in combination with AstraZeneca's Tagrisso

Genprex, based in Austin, Texas and Cambridge, Massachusetts, plans to use the proceeds to advance its clinical programs in non-small cell lung cancer, as well as for working capital and general corporate purposes. 

The company is developing a new approach to treating cancer, including its initial product candidate Oncoprex, which is an immunogene therapy for non-small cell lung cancer.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

14 minutes ago